TGX Stain-Free™ FastCast™ Acrylamide Kit, 7.5%
Bio-RadKit for hand casting 7.5% TGX Stain-Free polyacrylamide gels, includes acrylamide solutions and buffers
Kit for hand casting 7.5% TGX Stain-Free polyacrylamide gels, includes acrylamide solutions and buffers
Kit for hand casting 10% TGX Stain-Free polyacrylamide gels, includes acrylamide solutions and buffers
Kit for hand casting 12% TGX Stain-Free polyacrylamide gels, includes acrylamide solutions and buffers
Recombinant SARS-CoV-2 Spike Protein, S1 Subunit derived from E.coli
Recombinant SARS-CoV-2 Spike Protein, S2 Subunit derived from E.coli
Multi lingual single beam spectrophotometer, for life sciences measurements. Nano cells may be used
BioAquarius spectrophotometers, pre-programmed for DNA, RNA, protein and life science analyses.
A Novel Assay Based on the Expression of ILT-3 (CD85k) by the 2 Major Circulating DC Subsets: Performance Validation
Recombinant Human B-cell lymphoma 2 (BCL-2) protein, a key regulator of apoptosis (programmed cell death) and a well-established oncoprotein in many cancers.
Simple solution for screening activity of purified or recombinant lysine specific demethylase enzymes
Inhibitor of bone resorption; Inhibits farnesyl diphosphate (FPP) synthase
Alturas Analytics is a CRO specializing in preclinical and clinical bioanalysis
In this on-demand webinar, find out the latest methods for equines anti-doping analysis, and the analysis of challenging samples
Catch up on this expert on-demand webinar to discover a novel approach for in silico method development and robustness assessment
Explore the new technologies and techniques that promise to provide confidence and reproducibility in results
New results suggest the MammaTyper test could predict the likelihood of complete pathologic remission
Non-invasive, cell-free pre-natal DNA testing to be performed on QIAGEN’s GeneReader NGS System
A blood test for cancer DNA could predict if a woman is responding to the new breast cancer drug palbociclib, months earlier than current tests
Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit